A new survey of cancer doctors published in a research note from investment bank R.W. Baird provides some more reasons for investors to worry about Dendreon and its prostate cancer treatment Provenge, ...

Much has been said and written about the circumstances surrounding the launch of Dendreon’s innovation in cancer treatment, Provenge, a novel immunotherapeutic treatment for end-stage prostate cancer.

Dendreon's IMPACT study of its cancer vaccine Provenge beat the FDA's 22 percent "reduction in risk of death" standard by just half a percent: The company said it reduced "risk of death" by 22.5 ...

January 6, 2011 — Back in the fall of 2010, the Centers for Medicare and Medicaid Services (CMS) had a problem: their phone lines for an important presscast were at full capacity. As a result, there ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

One of the first big stories I wrote about at Forbes was the controversy over embryonic stem cells that raged in 2000 and 2001 and resulted in a major compromise announced by President Bush ten years ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

Medicare said this week it will pay for two cancer treatments with hefty price tags -- and lingering questions: Avastin, the controversial drug shot down by an Food and Drug Administration panel on ...

Biotechnology company Dendreon said Wednesday that sales of its prostate cancer drug Provenge continued to climb in the third quarter, although Dendreon took a larger loss as it built up its ...

Prostate cancer treatment zibotentan is looking like less of a threat to Dendreon's (Nasdaq: DNDN) Provenge after AstraZeneca (NYSE: AZN) said that it was stopping a phase 3 trial testing zibotentan ...

NEW YORK (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators and ...